Please login to the form below

Not currently logged in
Email:
Password:

Shire elects new chair

Susan Kilsby to replace Matthew Emmens who retires
Shire Susan Kilsby

Shire has announced that chairman Matthew Emmens will step down in April to be replaced by board member Susan Kilsby.

Emmens has been with Ireland-based pharma firm Shire since 2003, joining as chief executive before being appointed chairman in 2008.

During that time Shire has grown substantially, although has struggled in recent years with generic competition for big-selling attention deficit-hyperactivity disorder (ADHD) drug Adderall XR and plans to downsize in certain areas.

Kilsby, who takes over as chair on April 29, 2014, will have her work cut out as Shire looks to move its focus to the growing rare disease market, boosted by the recent purchase of Virophama and an alliance agreed last year with Santaris.

She joined the Shire board as a non-executive director in September 2011 and has been chair of the audit, compliance and risk committee since May 2013.

Prior to joining the company, Kilsby developed extensive experience in the financial sector, including serving as senior adviser at Credit Suisse.

Her other board memberships include director positions at Green Mountain Coffee Roasters, BBA Aviation and Coca-Cola Hellenic Bottling Company.

24th January 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics